Heart failure: novel therapeutic approaches
1Department of Pharmacology, Government Medical College, Surat, Gujarat, India.
Insights
New heart failure (HF) pharmacotherapies target novel pathways to improve treatment. Research explores agents impacting myocardial contractility, inflammation, fibrosis, metabolism, and oxidative stress for better HF management.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Science
Background:
- Heart failure (HF) remains a significant clinical challenge with substantial mortality and morbidity despite current therapies.
- Advances include beta-blockers and renin-angiotensin system antagonists, yet a critical need for improved treatments persists.
- Recent research has elucidated HF pathophysiology, identifying novel molecular targets.
Purpose of the Study:
- To review recent advancements in pharmacotherapy for heart failure.
- To highlight novel therapeutic targets and pharmacological agents for HF treatment.
- To discuss agents addressing myocardial contractility, inflammation, fibrosis, metabolism, and oxidative stress.
Main Methods:
- Literature review of recent advancements in heart failure pharmacotherapy.
- Analysis of novel molecular pathways and targets implicated in HF progression.
- Categorization of emerging pharmacological agents based on their mechanisms of action.
Main Results:
- Identification of multiple novel pathways and molecular sites contributing to HF progression.
- Development of new pharmacological agents targeting these identified sites.
- Emerging therapies focus on myocardial contractility, cytokines, inflammation, fibrosis, remodeling, metabolism, and oxidative stress.
Conclusions:
- Novel pharmacological agents targeting newly identified pathways show promise for heart failure treatment.
- Targeting specific molecular sites offers a promising strategy to improve outcomes in heart failure patients.
- Continued research into HF pathophysiology is crucial for developing next-generation therapies.
Abstract:
Heart failure (HF) is a complex clinical syndrome that can result from any structural or functional cardiac disorders that impairs the ability of the ventricle to fill with or eject blood. Despite effective medical interventions, mortality and morbidity remain substantial. There have been significant advances in the therapy of HF in recent decades, such as the introduction of beta-blockers and antagonists of the renin-angiotensin system but still there is a major unmet need for better therapies for HF. In the present era, pathophysiology of HF has been explored. Various novel pathways, molecular sites have been identified, which contribute to the progression of the disease. By targeting these sites, newer pharmacological agents have been developed, which can play a promising role in the treatment of HF. This article focuses on recent advancements in pharmacotherapy of HF, which include agents targeting myocardial contractility, cytokines and inflammation, fibrosis and remodeling, myocardial metabolism, oxidative stress, and other newly defined pathways.
Related Concept Videos
01:30Heart Failure V: Medical Management
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure VI: Adjunct Therapies
01:22Heart Failure Drugs: β-Blockers
01:26Heart Failure Drugs: Inotropic Agents
01:22Heart Failure Drugs: Diuretics